Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RNAZ
stocks logo

RNAZ

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2025Q2
FY2025Q3
--
--
-56.000
-90.68%
--
--
-8.680
-99.97%
--
--
-9.240
-93.75%
Estimates Revision
The market is revising No Change the revenue expectations for TransCode Therapeutics, Inc. (RNAZ) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -21.28%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-21.28%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Transcode Therapeutics Inc (RNAZ.O) is -6.63, compared to its 5-year average forward P/E of -2.02. For a more detailed relative valuation and DCF analysis to assess Transcode Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.02
Current PE
-6.63
Overvalued PE
0.56
Undervalued PE
-4.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
11.22
Current PS
0.00
Overvalued PS
34.89
Undervalued PS
-12.45
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

RNAZ News & Events

Events Timeline

(ET)
2025-10-14
08:12:02
Transcode Therapeutics' TTX-MC138 Meets Safety Milestone in Phase 1a Trial
select
2025-10-08 (ET)
2025-10-08
08:10:18
Transcode Therapeutics set to purchase Polynoma
select
2025-05-08 (ET)
2025-05-08
08:08:00
Transcode Therapeutics completes dosing of patients in Phase 1a cancer trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-17PRnewswire
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

  • Appointment of Dr. Michel Janicot: TransCode Therapeutics has appointed Dr. Michel Janicot as Senior Development Officer, bringing over 35 years of experience in drug development, particularly in oncology and RNA biology.

  • Focus on Oncology Pipeline: Dr. Janicot will support TransCode's strategic R&D initiatives and clinical development for its lead programs, TTX-MC138 and Seviprotimut-L, aimed at treating metastatic and recurrent cancers.

  • Dr. Janicot's Background: He holds a Ph.D. in Biochemistry and has held senior positions in various pharmaceutical companies, as well as founding a consulting firm focused on early-stage pharmaceutical development.

  • TransCode's Mission: TransCode Therapeutics is dedicated to advancing immuno-oncology and targeted therapies, with a focus on innovative treatments for advanced malignancies, leveraging its RNA platform.

[object Object]
Preview
8.5
10-08NASDAQ.COM
TransCode Purchases Polynoma from CK Life Sciences

  • Acquisition Announcement: TransCode Therapeutics has agreed to acquire Polynoma, a biotechnology company focused on immuno-oncology, which is developing a vaccine for melanoma treatment.

  • Investment for Development: Concurrently, TransCode secured a $25 million investment from CK Life Sciences to support the clinical development of its lead microRNA asset, TTX-MC138, into a Phase 2 trial.

[object Object]
Preview
8.5
10-08PRnewswire
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company

  • Acquisition Announcement: TransCode Therapeutics has acquired 100% of Polynoma, a biotechnology company developing the seviprotimut-L vaccine for melanoma, and received a $25 million equity investment from CK Life Sciences to support its clinical development.

  • Leadership Changes: Philippe Calais has been appointed as CEO while remaining Chairman, and Elizabeth Czerepak joins as an independent board member and Chairperson of the Audit Committee, with Tom Fitzgerald continuing as CFO.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Transcode Therapeutics Inc (RNAZ) stock price today?

The current price of RNAZ is 8.6357 USD — it has increased 2.69 % in the last trading day.

arrow icon

What is Transcode Therapeutics Inc (RNAZ)'s business?

TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

arrow icon

What is the price predicton of RNAZ Stock?

Wall Street analysts forecast RNAZ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNAZ is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Transcode Therapeutics Inc (RNAZ)'s revenue for the last quarter?

Transcode Therapeutics Inc revenue for the last quarter amounts to -4.54M USD, increased 110.78 % YoY.

arrow icon

What is Transcode Therapeutics Inc (RNAZ)'s earnings per share (EPS) for the last quarter?

Transcode Therapeutics Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Transcode Therapeutics Inc (RNAZ)'s fundamentals?

The market is revising No Change the revenue expectations for TransCode Therapeutics, Inc. (RNAZ) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -21.28%.
arrow icon

How many employees does Transcode Therapeutics Inc (RNAZ). have?

Transcode Therapeutics Inc (RNAZ) has 7 emplpoyees as of December 05 2025.

arrow icon

What is Transcode Therapeutics Inc (RNAZ) market cap?

Today RNAZ has the market capitalization of 8.14M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free